Entera Bio Ltd.
ENTX
$3.31+0.03 (0.91%)Nov 20
After-hours: $3.31 (-0.15%)
Entera Bio Ltd. (ENTX)
$3.31+0.03+0.91%Nov 20
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
YTD70%
M.cap.576 mn
Std.Dev, 1y1.72
Vol, bn0.0 (high)
RSI60
P/E—
MFI63
P/S—
ADX19 (no trend)
P/B2.10
Beta1.42
Div—
Debt/EBITDA—
Payout—
Price target
Buy 1 (100%)Hold 0 (0%)Sell 0 (0%)
Next earnings—
Earnings surprise
Short interest5.6% (+1.2%), 30 Oct 2026
Fund owners #23 (-6)
Insider ownership$19 mm
Insider selling—
Insider buying—
General
M.Cap$576M
Dividends—
Next report—
Forecast
Valuation
Target
P/E—
P/S—
P/B2.10
Fundamentals
5-y avg sales growth-35.1%
Debt / EBITDA0.00
ROE—
Altman Z-score5.61 (safe)
Technicals
RSI60
MFI63
Price / MA50+12.8% (high) ↑
Trend pattern
Financial Statements
No data available
Financial Statements
No data available
Team
Loading…
Team
Loading…
Leadership Changes
Sign in to view leadership changes
Sign in
No changes found
Insider Activity
Loading…
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Investor Presentations
Loading…
Options
Exp. from:to:
Strike from:to:
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
Stress Test
Loading…
About

Entera Bio is a pharmaceutical company developing large molecule drugs for unmet medical needs. EB612 and EB613 are its product candidates; EB612 is being tested for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is also in Phase I trials for non-union fractures. Entera Bio has a research agreement with Amgen to develop treatments for inflammatory diseases and other serious illnesses.

Headcount: 27
Address:Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
About

Entera Bio is a pharmaceutical company developing large molecule drugs for unmet medical needs. EB612 and EB613 are its product candidates; EB612 is being tested for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is also in Phase I trials for non-union fractures. Entera Bio has a research agreement with Amgen to develop treatments for inflammatory diseases and other serious illnesses.

https://www.enterabio.com
Beta 1.42